Jump to any asset
850 assets, updated daily
As of September 11, 2026, iShares Biotechnology ETF (IBB) trades at $203.62. RSI at 33 is in neutral territory, and the price is above its 50-day average of $199.11.
iShares Biotechnology ETF (IBB)
iShares Biotechnology ETF NASDAQ
$203.62
0.9800 (0.48%)
Latest Price
AI Analyst Consensus
55 / 100
The iShares Biotechnology ETF (IBB) is an exchange-traded fund designed to offer broad exposure to U.S.-listed biotechnology companies, including those involved in therapeutics, genetic medicine, and diagnostics. As of September 2026, IBB is trading at $203.62, having experienced a significant year-to-date return of 23.98%. The fund's strategy focuses on companies within the research-intensive biotechnology sector, serving as a sector-specific instrument for investors. Despite a recent downturn indicated by its RSI and position below the 20-day EMA, the ETF has shown resilience by staying above its longer-term moving averages.
IBB Price Analysis
Market Metrics
Open
$204.39
Day Range
$202.75 to $205.17
Prev Close
$202.64
Volume
71.7K
52-Week Range
$137.64 to $217.12
Market Cap
$11.78B
IBB Fund Facts
iShares Biotechnology ETF is an exchange-traded fund that provides broad exposure to U.S.-listed biotechnology companies. The fund is designed to track a biotechnology-focused index and typically holds a diversified basket of large, mid, and smaller biotechnology names, along with select life sciences tools and services companies that support drug discovery and research. Its portfolio includes firms involved in areas such as therapeutics, genetic medicine, diagnostics, and advanced research platforms.
Issuer
iShares
Category
Health
Inception
Feb 5, 2001
Expense ratio
0.44%
Net assets
$10.47B
NAV
$207.29
Distribution yield
0.20%
YTD return
23.98%
Turnover
27.00%
Sector weights
Healthcare
100.0%
Trailing returns vs category
| Period | IBB | Category |
|---|---|---|
| YTD | 23.98% | -2.39% |
| 1 month | 12.11% | 1.70% |
| 3 months | 21.34% | -3.03% |
| 1 year | 51.66% | 21.31% |
| 3 years | 17.87% | 6.58% |
| 5 years | 4.20% | 1.49% |
| 10 years | 8.63% | 8.56% |
Fund reference data as of Sep 11, 2026. Expense ratio and net assets are reported by the fund; returns are total returns and can differ from price change.
IBB Analysis
AI Technical Analysis
IBB's nearest resistance is its 20-day Exponential Moving Average (EMA) at $206.84, which the price is currently trading below. The Relative Strength Index (RSI) stands at 33.07, indicating bearish momentum. However, the ETF is trading above its 50-day Simple Moving Average (SMA) of $199.11 and its 200-day SMA of $178.32, suggesting that longer-term support levels remain intact. The Stochastic indicator at 10.83 also points towards oversold conditions, potentially signaling a near-term bounce.
ProTips
- Monitor the 20-day EMA as a key short-term resistance level for IBB.
- Keep an eye on the RSI for signs of a shift from bearish to neutral or overbought conditions.
- Consider the broader healthcare sector trends and regulatory environment for sector-specific risks.
- Evaluate the performance of IBB's top underlying holdings to gauge sector health.
Market Outlook
The outlook for the iShares Biotechnology ETF (IBB) is cautiously optimistic, balancing short-term technical weakness with long-term sector potential. While the ETF is currently trading below its 20-day EMA and exhibits bearish RSI momentum, its position above key longer-term support levels suggests resilience. The biotechnology sector continues to be a driver of innovation in healthcare, which should support IBB over the next 6-12 months. Potential catalysts for upside include positive clinical trial results from major holdings and favorable regulatory developments. Conversely, increased sector rotation, unexpected adverse regulatory actions, or a significant macroeconomic downturn could pressure the ETF. The median projection from a Monte Carlo simulation suggests a base price of $271.92 by 2030, indicating substantial long-term growth potential.
Market Correlations
How this etf moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.59
Moderate correlation
Nasdaq 100 (QQQ)
+0.50
Moderate correlation
Bitcoin (BTC)
+0.05
Weak correlation
Gold (XAU)
+0.20
Weak correlation
Check Custom Correlation
Calculating correlation...
Key Statistics
| Net Assets (Market Cap) | 11.78B |
|---|---|
| Yield | 0.2021% |
| Day High | $205.17 |
| Day Low | $202.75 |
| 52 Week High | 217.12 |
| 52 Week Low | 137.64 |
The iShares Biotechnology ETF (IBB) holds approximately 99.92% in stocks, primarily within the Healthcare sector, reflecting its focused investment strategy. With net assets totaling $10.47 billion and an expense ratio of 0.44%, IBB provides diversified access to companies developing innovative medicines and scientific technologies. The fund's overview highlights its role in capturing exposure to one of the most research-intensive areas of the healthcare market.
Earnings & Growth Analysis
Recent earnings reports for underlying biotechnology companies show mixed results. In late June 2026, an earnings release showed an actual EPS of -0.01 against an estimate of -0.01, with no surprise percentage and a 0.62% price change. Prior to that, in late May 2026, an earnings report revealed an actual EPS of -0.05 versus an estimate of -0.08, representing a 37.5% positive surprise and a 0.27% price change. These figures suggest that while some companies are meeting or beating low expectations, the overall earnings picture for the sector remains challenging, with many firms operating at a loss.
Key Risks
IBB faces concentration risk due to its focus on the biotechnology sector, making it susceptible to sector-specific headwinds and regulatory changes. The current bearish RSI reading and price below the 20-day EMA suggest potential for further short-term downside. Macroeconomic shifts impacting healthcare spending or R&D investment could also pose a risk to the fund's performance.
Technical Indicators
| RSI (14) | 33.07 |
|---|---|
| MACD | 2.31 |
| SMA 50 | 199.11 |
| SMA 200 | 178.32 |
RSI
Bearish
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($199.11) above the 200-day SMA ($178.32), price action is firmly bullish above key moving averages.
IBB Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies (click to switch)
CONSERVATIVE
$201.58
Slight discount to current
Wait for small dip
AGGRESSIVE
$203.62
At current price
Enter now if confident
Risk Management
STOP LOSS
$195.54
MAX LOSS
-3.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (33.1) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$207.63
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$211.66
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$217.71
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
ETF Investment Disclaimer
This AI-generated analysis of IBB is for educational purposes only and does not constitute investment advice. ETFs are subject to market risk including possible loss of principal. Performance depends on the underlying index or assets tracked. Read the fund prospectus before investing. Past performance does not guarantee future results. Generated on September 11, 2026.Growth of $10,000
A $10,000 investment in IBB in September 2016 would be worth about $21,174 today, compared with about $35,030 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in IBB today could grow to about $20,609 by 2036 in the base case, with a bull case near $52,824 and a bear case around $8,041. Projections are statistical simulations, not guarantees.
IBB ETF Price Prediction: 2030
CleaRank's simulation projects a price near $272 for IBB by 2030 in the base case, from $204 today (1.3x over 4 years). The downside path ends near $150. These are outcomes of a Monte Carlo simulation run on IBB's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $163 | $219 | $295 |
| 2028 | $154 | $235 | $358 |
| 2029 | $151 | $253 | $424 |
| 2030 | $150 | $272 | $493 |
| 2031 | $150 | $292 | $569 |
| 2032 | $152 | $314 | $651 |
| 2033 | $154 | $338 | $742 |
| 2034 | $156 | $363 | $843 |
| 2035 | $160 | $390 | $953 |
| 2036 | $164 | $420 | $1,076 |
Method: 10,000 simulated price paths using IBB's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
Frequently Asked Questions
What is the expense ratio for the iShares Biotechnology ETF (IBB) and what does it cost per $10,000 invested?
The iShares Biotechnology ETF (IBB) has an expense ratio of 0.44%. This means an investment of $10,000 would incur an annual cost of $44.00.
What are the primary sectors and asset allocations for the iShares Biotechnology ETF (IBB)?
The iShares Biotechnology ETF (IBB) is heavily concentrated in the Healthcare sector, representing 100% of its holdings. The fund's asset allocation is 99.92% in stocks.
What is the distribution yield for the iShares Biotechnology ETF (IBB)?
The iShares Biotechnology ETF (IBB) has a distribution yield of 0.20%.
How has the iShares Biotechnology ETF (IBB) performed against its category over various periods?
As of September 2026, IBB has outperformed its category year-to-date (23.98% vs -2.39%), over 1 year (51.66% vs 21.31%), and over 3 years (17.87% vs 6.58%). It also shows stronger 5-year (4.20% vs 1.49%) and 10-year (8.63% vs 8.56%) returns, though the 1-month (12.11% vs 1.70%) and 3-month (21.34% vs -3.03%) periods show a divergence with the category experiencing a downturn.
What is the price prediction for the IBB ETF in 2030?
Based on Monte Carlo simulations, the base case price for the IBB ETF in 2030 is $271.92, with a downside scenario of $149.94. These are statistical simulation outcomes, not price targets or guarantees.
What are the key risks associated with investing in the iShares Biotechnology ETF (IBB)?
Key risks for IBB include significant concentration in the biotechnology sector, making it vulnerable to sector-specific downturns and regulatory changes. Additionally, the ETF's performance can be impacted by broader macroeconomic factors affecting healthcare R&D and spending.
How has the iShares Biotechnology ETF (IBB) performed recently in September 2026?
In September 2026, the iShares Biotechnology ETF (IBB) is trading at $203.62. While its RSI is bearish at 33.07, it remains above its 50-day and 200-day moving averages ($199.11 and $178.32), indicating some underlying support despite short-term weakness.